Disulfiram Repurposing Across Therapeutic Indications: Molecular Mechanisms, Evidence Appraisal, and a Systematic Review of Its Use in Lyme Borreliosis
Current Issues in Molecular Biology · 09.11.2026 · 48 (11) · 1185
DOI: 10.3390/cimb48111185 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 09.11.2026. Verfasst von Violeta Popovici und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Disulfiram (tetraethylthiuram disulfide, DSF), licensed for alcohol use disorder since 1951, is among the most studied drug-repurposing candidates and has been prescribed off-label for Lyme borreliosis since 2016. This hybrid review asks what supports that practice, appraising the Lyme evidence against disulfiram’s record in other repurposing indications. We provided a narrative review of DSF and its bioactive metabolites’ pharmacology, molecular targets, and toxicology. We also included a separate section systematically reviewing DSF in Lyme borreliosis following the PRISMA 2020 Guide. PubMed, Europe PMC, CENTRAL, bioRxiv, medRxiv, and ClinicalTrials.gov were searched from inception, while risk of bias was assessed using ROBINS-I, RoB 2, and SYRCLE; certainty was analyzed using GRADE. DSF is a prodrug acting through twenty-one documented targets, yet only alcohol use disorder rests on regulatory-grade evidence; oncology results are contradictory, and other indications remain preclinical. Nine primary studies addressed Lyme borreliosis, with five human reports contributing 96 participant entries and 93 unique individuals. Preclinical findings conflict, the largest dataset is uncontrolled, and the only randomized trial stopped early. Evidence on DSF repurposing shows strong preclinical support and small or inconsistent controlled results; a few well-powered randomized trials comparing it to standard care reported no clear benefits, but increased toxicity. In Lyme borreliosis, certainty of DSF benefits is very low, and certainty of dose-dependent harm is moderate, including one fatal outcome. No human study measured a microbiological endpoint, and all preclinical work used B. burgdorferi sensu stricto, leaving the evidence indirect for European genospecies.
Zitieren
APA
Popovici, V., Ciumasu-Rimbu, M., Boca, R., & Ozon, E. A. (2026). Disulfiram Repurposing Across Therapeutic Indications: Molecular Mechanisms, Evidence Appraisal, and a Systematic Review of Its Use in Lyme Borreliosis. Current Issues in Molecular Biology, 48(11), 1185. https://doi.org/10.3390/cimb48111185
Vancouver
Popovici V, Ciumasu-Rimbu M, Boca R, Ozon EA. Disulfiram Repurposing Across Therapeutic Indications: Molecular Mechanisms, Evidence Appraisal, and a Systematic Review of Its Use in Lyme Borreliosis. Current Issues in Molecular Biology. 2026;48(11):1185. doi:10.3390/cimb48111185
BibTeX
@article{Popovici2026,
author = {Popovici, Violeta and Ciumasu-Rimbu, Malina and Boca, Rodica and Ozon, Emma Adriana},
title = {Disulfiram Repurposing Across Therapeutic Indications: Molecular Mechanisms, Evidence Appraisal, and a Systematic Review of Its Use in Lyme Borreliosis},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {11},
pages = {1185},
doi = {10.3390/cimb48111185}
}
EUVIMED